Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Technology Digest Bermuda.
Press releases published on September 2, 2025
PolarityBio Announces Launch of Expanded Access Treatment Protocol to Provide Continued Access to SkinTE® for Patients with Wagner 1 Diabetic Foot Ulcers
GlobeNewswire
·
September 2, 2025
SALT LAKE CITY, Sept. 02, 2025 (GLOBE NEWSWIRE) -- PolarityBio, a clinical-stage biotechnology company focused on addressing unmet needs in wound healing through innovation in autologous regenerative skin multicellular therapy, today announced the launch …
Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
September 2, 2025
MIAMI, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity …
Fluent, Inc. to Participate in 18th Annual Barrington Research Virtual Fall Investment Conference
GlobeNewswire
·
September 2, 2025
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Fluent, Inc. (NASDAQ: FLNT), a leader in commerce media, today announced that Don Patrick, Chief Executive Officer, and Ryan Perfit, Chief Financial Officer, will participate in the 18th Annual Barrington …
Roper Technologies to present at Goldman Sachs Technology Conference
GlobeNewswire
·
September 2, 2025
SARASOTA, Fla., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Roper Technologies, Inc. (Nasdaq: ROP) announced that it is presenting at the Goldman Sachs Communacopia + Technology Conference on Tuesday, September 9, 2025, at 8:50 AM (Pacific Time) at the Palace in …
Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial
GlobeNewswire
·
September 2, 2025
– First patient treatment marks successful initiation of multi-center pilot study in Alpha DaRT U.S. pancreatic cancer program – – Study explores Alpha DaRT® combined with chemotherapy in patients with newly diagnosed unresectable locally advanced or …
PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference
GlobeNewswire
·
September 2, 2025
PETACH TIKVA, Israel, Sept. 02, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Dalit Hazan, Deputy CEO, EVP R…
SEALSQ Outlines Strategic Steps to Protect Cryptocurrencies with Post-Quantum Technology and Advances NIST Certification with VaultIC 408
GlobeNewswire
·
September 2, 2025
Geneva, Switzerland, Sept. 02, 2025 (GLOBE NEWSWIRE) -- SEALSQ Corp (NASDAQ: LAES) ("SEALSQ" or "Company"), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, today announced a …
From Field to Lab: Regula Upgrades Its Forensic Light Kit with Full Ecosystem Integration for Seamless Crime Investigations
GlobeNewswire
·
September 2, 2025
RESTON, Va., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Regula, a global developer of forensic devices and identity verification solutions, has upgraded its Regula 3116M, a portable forensic light kit designed for high-precision detection and documentation of …
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
GlobeNewswire
·
September 2, 2025
SEATTLE and VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of …
Lantheus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
GlobeNewswire
·
September 2, 2025
BEDFORD, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, …
Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress
GlobeNewswire
·
September 2, 2025
THE WOODLANDS, Texas, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced that a post-hoc analysis (“Efficacy of Sotagliflozin Among Older Adults: A Pooled Analysis of SCORED and SOLOIST-WHF”) of clinical data was …
Structure Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences
GlobeNewswire
·
September 2, 2025
SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today …
24/7 Market News Reports TEN Holdings Beta Days Are Here
GlobeNewswire
·
September 2, 2025
DENVER, Sept. 02, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, reports that TEN Holdings (NASDAQ: XHLD), a provider of event planning, …
Foresight and Thermal Camera Giant Guide Infrared Collaborate to Develop Cost-Effective Stereoscopic Cameras
GlobeNewswire
·
September 2, 2025
The joint effort combines advanced, affordable infrared imaging and cutting-edge automotive integration to enhance 3D perception and safety in all driving conditions Ness Ziona, Israel, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Foresight Autonomous Holdings Ltd. …
Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board
GlobeNewswire
·
September 2, 2025
NEEDHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today …
IMUNON to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
September 2, 2025
LAWRENCEVILLE, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that a pre-recorded presentation from the Company will be available on …
Mainz Biomed Announces Registration of ColoAlert in the United Kingdom
GlobeNewswire
·
September 2, 2025
BERKELEY, Calif. and MAINZ, Germany, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces today that ColoAlert …
Nkarta to Participate in a September Investor Conference
GlobeNewswire
·
September 2, 2025
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor …
OSS Announces Upcoming Investor Events
GlobeNewswire
·
September 2, 2025
ESCONDIDO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- One Stop Systems, Inc. (OSS or the Company) (Nasdaq: OSS), a leading provider of rugged, enterprise-class compute solutions for AI, machine learning (ML), and sensor processing at the edge, today …
Step Pharma announces first participant dosed in a phase 1b clinical trial of dencatistat for essential thrombocythaemia
GlobeNewswire
·
September 2, 2025
Start of the phase 1b trial in a new indication expands Step Pharma’s clinical programme, building on the development of dencatistat in lymphoma and solid tumours This milestone marks the third indication for dencatistat, a first-in-class, highly selective …